These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12824026)

  • 21. Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time.
    Szalony JA; Suleymanov OD; Salyers AK; Panzer-Knodle SG; Blom JD; LaChance RM; Case BL; Parlow JJ; South MS; Wood RS; Nicholson NS
    Thromb Res; 2003; 112(3):167-74. PubMed ID: 14967414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and structure-activity relationships of benzoxazinone-based factor Xa inhibitors.
    Huang W; Zhang P; Zuckett JF; Wang L; Woolfrey J; Song Y; Jia ZJ; Clizbe LA; Su T; Tran K; Huang B; Wong P; Sinha U; Park G; Reed A; Malinowski J; Hollenbach SJ; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2003 Feb; 13(3):561-6. PubMed ID: 12565972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterocyclic thrombin inhibitors. Part 1: design and synthesis of amidino-phenoxy quinoline derivatives.
    Ries UJ; Priepke HW; Hauel NH; Haaksma EE; Stassen JM; Wienen W; Nar H
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2291-5. PubMed ID: 12824020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.
    Dudley DA; Bunker AM; Chi L; Cody WL; Holland DR; Ignasiak DP; Janiczek-Dolphin N; McClanahan TB; Mertz TE; Narasimhan LS; Rapundalo ST; Trautschold JA; Van Huis CA; Edmunds JJ
    J Med Chem; 2000 Nov; 43(22):4063-70. PubMed ID: 11063603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.
    Lu T; Markotan T; Ballentine SK; Giardino EC; Spurlino J; Crysler CS; Brown K; Maryanoff BE; Tomczuk BE; Damiano BP; Shukla U; End D; Andrade-Gordon P; Bone RF; Player MR
    J Med Chem; 2010 Feb; 53(4):1843-56. PubMed ID: 20102150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting thrombin and factor VIIa: design, synthesis, and inhibitory activity of functionally relevant indolizidinones.
    Hanessian S; Therrien E; Granberg K; Nilsson I
    Bioorg Med Chem Lett; 2002 Oct; 12(20):2907-11. PubMed ID: 12270173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-based design of P3 moieties in the peptide mimetic factor VIIa inhibitor.
    Kadono S; Sakamoto A; Kikuchi Y; Oh-eda M; Yabuta N; Yoshihashi K; Kitazawa T; Suzuki T; Koga T; Hattori K; Shiraishi T; Haramura M; Kodama H; Ono Y; Esaki T; Sato H; Watanabe Y; Itoh S; Ohta M; Kozono T
    Biochem Biophys Res Commun; 2005 Feb; 327(2):589-96. PubMed ID: 15629154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of novel heterocyclic factor VIIa inhibitors.
    Rai R; Kolesnikov A; Sprengeler PA; Torkelson S; Ton T; Katz BA; Yu C; Hendrix J; Shrader WD; Stephens R; Cabuslay R; Sanford E; Young WB
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2270-3. PubMed ID: 16460932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity.
    Wiley MR; Weir LC; Briggs S; Bryan NA; Buben J; Campbell C; Chirgadze NY; Conrad RC; Craft TJ; Ficorilli JV; Franciskovich JB; Froelich LL; Gifford-Moore DS; Goodson T; Herron DK; Klimkowski VJ; Kurz KD; Kyle JA; Masters JJ; Ratz AM; Milot G; Shuman RT; Smith T; Smith GF; Tebbe AL; Tinsley JM
    J Med Chem; 2000 Mar; 43(5):883-99. PubMed ID: 10715155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors.
    Buckman BO; Mohan R; Koovakkat S; Liang A; Trinh L; Morrissey MM
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2235-40. PubMed ID: 9873520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: transition state inhibitors.
    Bachand B; Tarazi M; St-Denis Y; Edmunds JJ; Winocour PD; Leblond L; Siddiqui MA
    Bioorg Med Chem Lett; 2001 Feb; 11(3):287-90. PubMed ID: 11212093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors.
    Klingler O; Matter H; Schudok M; Bajaj SP; Czech J; Lorenz M; Nestler HP; Schreuder H; Wildgoose P
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1463-7. PubMed ID: 12668013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant.
    Zhang E; St Charles R; Tulinsky A
    J Mol Biol; 1999 Feb; 285(5):2089-104. PubMed ID: 9925787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors.
    Quan ML; Wong PC; Wang C; Woerner F; Smallheer JM; Barbera FA; Bozarth JM; Brown RL; Harpel MR; Luettgen JM; Morin PE; Peterson T; Ramamurthy V; Rendina AR; Rossi KA; Watson CA; Wei A; Zhang G; Seiffert D; Wexler RR
    J Med Chem; 2014 Feb; 57(3):955-69. PubMed ID: 24405333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studies.
    Wong PC; Luettgen JM; Rendina AR; Kettner CA; Xin B; Knabb RM; Wexler R; Priestley ES
    Thromb Haemost; 2010 Aug; 104(2):261-9. PubMed ID: 20589312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors.
    Arnaiz DO; Zhao Z; Liang A; Trinh L; Witlow M; Koovakkat SK; Shaw KJ
    Bioorg Med Chem Lett; 2000 May; 10(9):957-61. PubMed ID: 10853668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimization of a coagulation factor VIIa inhibitor found in factor Xa inhibitor library.
    Sagi K; Fujita K; Sugiki M; Takahashi M; Takehana S; Tashiro K; Kayahara T; Yamanashi M; Fukuda Y; Oono S; Okajima A; Iwata S; Shoji M; Sakurai K
    Bioorg Med Chem; 2005 Mar; 13(5):1487-96. PubMed ID: 15698764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, and biological evaluation of pyrazinones containing novel P1 needles as inhibitors of TF/VIIa.
    Trujillo JI; Huang HC; Neumann WL; Mahoney MW; Long S; Huang W; Garland DJ; Kusturin C; Abbas Z; South MS; Reitz DB
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4568-74. PubMed ID: 17566736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
    Wong PC; Jiang X
    Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors.
    Zhao Z; Arnaiz DO; Griedel B; Sakata S; Dallas JL; Whitlow M; Trinh L; Post J; Liang A; Morrissey MM; Shaw KJ
    Bioorg Med Chem Lett; 2000 May; 10(9):963-6. PubMed ID: 10853669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.